Stay updated on IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib
Sign up to get notified when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.

Latest updates to the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedLocation entry updated to Padova, Veneto, Italy (35128), replacing Padua for the site.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedThe page's revision label was updated from v3.4.3 to v3.5.0. No substantive study content changes are indicated.SummaryDifference0.0%

- Check35 days agoChange DetectedAdded Hepatocellular carcinoma as a topic. Included a Resources section with a link to the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check42 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3 on the site.SummaryDifference0.0%

- Check65 days agoChange DetectedRevision: v3.4.2 is now displayed, replacing v3.4.1, indicating a minor site update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check72 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed.SummaryDifference0.0%

Stay in the know with updates to IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib
Enter your email address, and we'll notify you when there's something new on the IMbrave150 Clinical Trial: Atezo-Bev vs. Sorafenib page.